尾加压素Ⅱ在肺癌患者血浆中的表达及其临床意义  

Expression of Urotensin-Ⅱ in Blood Plasma of Lung Cancer Patients and Its Significance

作　　者：高鸿敏[1] 于忠和[1] 田桂珍[2] 张延利[1] 郝淑玲[1] 

机构地区：[1]北京军区总医院肿瘤诊疗中心,北京市100700 [2]北京军区263医院呼吸内科

出　　处：《中国肿瘤临床》2009年第20期1176-1178,共3页Chinese Journal of Clinical Oncology

基　　金：国家自然科学基金资助(编号:30370632)~~

摘　　要：目的:探讨尾加压素Ⅱ(U-Ⅱ)在肺癌患者血浆中的表达及其与肺癌分期及病理类型的关系。方法:采用放射免疫分析法测定16例健康人,35例非肺癌患者及74例肺癌患者血浆中U-Ⅱ含量,并进行统计学分析。结果:健康对照组血浆U-Ⅱ含量2.836±1.159pmol/l,肺癌组U-Ⅱ血浆含量3.539±1.228pmol/l,两者相比有显著差异(P<0.05);非肺癌组血浆U-Ⅱ含量2.925±0.922pmol/l,与肺癌组相比有显著差异。小细胞肺癌组血浆U-Ⅱ含量2.867±1.836pmol/l,非小细胞肺癌组血浆U-Ⅱ含量3.223±1.905pmol/l,两者相比差异无统计学意义(P>0.05)。Ⅰ-Ⅲ期肺癌组血浆U-Ⅱ含量明显低于Ⅳ期肺癌组,差异有统计学意义(P<0.05)。结论:U-Ⅱ在肺癌血浆申的表达水平增高,且U-Ⅱ表达水平与肺癌的分期及有无远处转移有关,与肺癌的病理类型无关。提示U-Ⅱ通过自分泌/旁分泌的方式,在肺癌的发生发展、侵袭及转移中起重要作用。深入研究U-Ⅱ可深化肺癌发病机制,对进一步揭示肺癌的发病机理有重要意义。Abstract Objective： To investigate the expression of Urotensin- Ⅱ （U-Ⅱ） in plasma of lung cancer patients and to explore the relationship of U-Ⅲ with the stage and pathological type of lung cancer. Methods： We detected the content of U- Ⅱ in plasma of 16 healthy adults, 35 non-lung cancer patients and 74 lung cancer patients using radio immunoassay. Results： The content of U-Ⅱ was 2.836＋ 1.159pmol/L in healthy controls and 3.539±1.228pmol/L in lung cancer patients, with significant difference （P〈0.05）. The content of U- Ⅱ in non-lung cancer patients was 2.925±0.922pmol/L, significantly different from that in lung cancer patients （P〈0.05）. The content of U-Ⅲ was 2.867±1.836 pmol/L in small cell lung cancer patients and 3.223±1.905 pmol/L in non- small cell lung cancer patients, with no significant difference （P〉0.05）. However, the content of U-Ⅱ in stage Ⅰ -Ⅲ lung cancer patients was significantly different from that in stage IV patients （P〈0.05）. Conclusion： The expression of U-Ⅱ in the plasma of lung cancer patients is increased. The expression of U- Ⅲ is correlated with the stage of lung cancer and distant metastasis. There is no significant correlation between the expression of U- Ⅱ and the pathological type of lung cancer. U-Ⅱ might have possible regulatory actions in the growth of lung cancer via an autocrine/paracrine path.

关 键 词：肺肿瘤 尾加压素Ⅱ 机制 

分 类 号：R734.2[医药卫生—肿瘤] R541.6[医药卫生—临床医学]